Strong Memorial Hospital is among a select few in the U.S. offering Carvykti, a treatment for multiple myeloma, a cancer in ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer patients in remission ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

A new research project is aiming to uncover why some cases of myeloma are more aggressive and harder to treat. The three-year study, led by Dr John Jones at Brighton and Sussex Medical School and ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...